ADARx Pharmaceuticals, Late-Stage Biotech Developing Potent, Durable siRNA Medicines ...

ADARx Pharmaceuticals, a late-stage biotech developing potent siRNA medicines, filed for a Nasdaq IPO to fund clinical programs targeting diseases like hereditary angioedema, thrombotic disease, and neurodegeneration, with notable FDA Fast Track and orphan drug designations.

This Wire brief sits within Fusion42's coverage of Biotech.